Xtl Biopharmaceuticals annual current ratio
2016
2017
2022
2023
2024
2025
Xtl Biopharmaceuticals Current Ratio Growth & History (XTLB)
Xtl Biopharmaceuticals's current ratio was 0.40 for fiscal 2025.
View full Xtl Biopharmaceuticals company overviewXtl Biopharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.40 | −0.21 | −34.90% |
| 2024 | 2024-12-31 | 0.61 | −9.32 | −93.89% |
| 2023 | 2023-12-31 | 9.93 | −10.42 | −51.20% |
| 2022 | 2022-12-31 | 20.35 | — | — |
| 2017 | 2017-12-31 | 20.69 | 12.34 | +147.88% |
| 2016 | 2016-12-31 | 8.35 | — | — |
Xtl Biopharmaceuticals quarterly current ratio
Q4.16
Q4.17
Q4.23
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.40 | −0.21 | −34.90% |
| Q2 2025 | 2025-06-30 | 0.70 | — | — |
| Q4 2024 | 2024-12-31 | 0.61 | −9.32 | −93.89% |
| Q4 2023 | 2023-12-31 | 9.93 | — | — |
| Q4 2017 | 2017-12-31 | 20.69 | 12.34 | +147.88% |
| Q4 2016 | 2016-12-31 | 8.35 | — | — |
Xtl Biopharmaceuticals current ratio trends
Between the periods ended 2016-12-31 and 2025-12-31, Xtl Biopharmaceuticals's current ratio decreased from 8.35 to 0.40, a change of −7.95. The latest reported quarter, Q4 2025, shows 0.40.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xtl Biopharmaceuticals source filings ↗